Complete Guide to Sleep Medications
A balanced guide to prescription and OTC sleep medications — benzodiazepines, Z-drugs, melatonin receptor agonists, and newer options — including tolerance risks, DEA scheduling, and when medication is appropriate.
Understanding Insomnia
Insomnia is the most common sleep disorder — characterized by difficulty falling asleep, staying asleep, or waking too early, despite adequate opportunity for sleep. It affects 10–15% of adults chronically and up to 30% occasionally.
Insomnia is classified as: - Short-term (acute): Lasting days to weeks, often triggered by stress, illness, or life events. Often resolves when the trigger resolves. - Chronic: Occurring at least 3 nights per week for 3+ months. Typically involves a cycle of anxiety about sleep that perpetuates wakefulness.
Medications are most appropriate for short-term or acute insomnia, or as a bridge while behavioral treatments are put in place.
Cognitive Behavioral Therapy First
Cognitive behavioral therapy for insomnia (CBT-I) is the gold standard first-line treatment for chronic insomnia — more effective and more durable than medications in head-to-head trials. Unlike drugs, CBT-I produces lasting improvement without dependence or side effect risks.
CBT-I techniques include sleep restriction, stimulus control, relaxation training, and cognitive restructuring. It requires motivation and effort but consistently outperforms medication in long-term follow-up. Medication may still have a role alongside CBT-I, particularly in the short term.
Z-Drugs: Non-Benzodiazepine Hypnotics
Z-drugs (zolpidem/Ambien, zaleplon/Sonata, eszopiclone/Lunesta) are among the most prescribed prescription sleep medications. Despite being structurally different from benzodiazepines, they work on the same GABA-A receptors — acting as partial agonists at the benzodiazepine site.
Z-drugs produce sedation, reduce sleep latency (time to fall asleep), and improve sleep maintenance (staying asleep). They are generally shorter-acting than benzodiazepines and have less effect on sleep architecture.
Notable concerns:
- Complex sleep behaviors: zolpidem in particular is associated with sleepwalking, sleep-driving, and sleep-eating — sometimes with no memory of the events. The FDA requires a black box warningBlack Box Warning The strongest safety warning issued by the FDA, appearing in a black-bordered box at the top of a drug's prescribing information. Black box warnings alert healthcare providers to serious or life-threa
Benzodiazepine Hypnotics
Benzodiazepines approved specifically for insomnia include temazepam (Restoril), triazolam (Halcion), flurazepam, and estazolam. Other benzodiazepines (diazepam, lorazepam, clonazepam) are used off-label.
They reduce anxiety and produce sedation by enhancing GABA activity broadly. Longer-acting benzodiazepines may cause next-day grogginess; shorter-acting ones (triazolam) carry more rebound insomnia risk.
DEA Scheduling of Sleep Medications
| Medication | DEA ScheduleDEA Schedule The classification system used by the Drug Enforcement Administration to categorize controlled substances based on their accepted medical use and potential for abuse. Schedule I drugs (e.g., heroin) h |
|---|---|
| Zolpidem, zaleplon, eszopiclone (Z-drugs) | Schedule IV |
| Temazepam, triazolam (benzo hypnotics) | Schedule IV |
| Ramelteon (melatonin agonistAgonist A drug that binds to a receptor and activates it, producing a biological response that mimics the body's natural signaling molecules. Full agonists produce the maximum possible effect, while partial a ) |
Not scheduled |
| Suvorexant, lemborexant (DORAs) | Schedule IV |
| Doxepin (low-dose antidepressant) | Not scheduled |
| Diphenhydramine (OTC) | Not scheduled |
Schedule IV means accepted medical use with lower abuse potential than Schedule III, but still requiring prescriptions and having misuse risk.
toleranceToleranceA decrease in a drug's effect over time with repeated administration, requiring higher doses to achieve the same response. Tolerance develops through receptor downregulation, enzyme induction, or othe
-and-dependence-concerns">Tolerance and Dependence Concerns
Both Z-drugs and benzodiazepine hypnotics can produce tolerance — reduced sleep-inducing effect over time with nightly use. This means:
- They work best for short-term use (2–4 weeks is a common guideline)
- Long-term nightly use often requires dose escalation to maintain effect
- Physical dependence develops, causing rebound insomnia (worse sleep than before treatment) if stopped abruptly
- Rebound insomnia can persist for 1–2 weeks after stopping, which may lead patients to resume the medication
Stopping benzodiazepines or Z-drugs after prolonged use requires gradual tapering.
Melatonin Receptor Agonists
Ramelteon (Rozerem) is a melatonin receptor agonist — it specifically activates MT1 and MT2 receptors in the suprachiasmatic nucleus (the brain's circadian clock), mimicking the sleep-promoting effect of endogenous melatonin.
Key advantages: - No abuse potential — not a controlled substance - No next-day cognitive impairment - No rebound insomnia or withdrawal
Key limitation: It primarily reduces sleep onset time but has little effect on sleep maintenance. It is best for people who cannot fall asleep but can stay asleep once they do.
OTC melatonin supplements (not a drug — not FDA-regulated as such) work similarly but with inconsistent quality control and variable doses (products often contain more melatonin than labeled). Effective OTC doses are typically 0.5–3 mg, not the 10 mg tablets commonly sold.
Dual Orexin Receptor Antagonists (DORAs)
DORAs are a newer class that works by blocking orexin (hypocretin) receptors. Orexin is a neurotransmitter that promotes wakefulness — DORAs reduce wakefulness drive rather than inducing sedation via GABA. This is a fundamentally different approach.
Examples: suvorexant (Belsomra), lemborexant (Dayvigo).
Advantages over traditional sleep medications: - Less cognitive impairment - Minimal next-day hangover - Lower dependence potential (though still Schedule IV)
They are approved for both sleep onset and sleep maintenance insomnia. Suvorexant can cause vivid dreams or sleep paralysis in some patients.
OTC Sleep Aids
Over-the-counterOver-the-Counter Medications that can be purchased without a prescription, deemed safe for consumer use when following the label directions. The FDA determines OTC status based on a drug's safety profile, abuse potent
- Diphenhydramine (ZzzQuil, Unisom SleepTabs, Benadryl)
- Doxylamine (Unisom SleepTabs — different from ZzzQuil version)
These cause sedation by blocking histamine H1 receptors in the brain. Tolerance to the sedating effect develops within just 3–4 days of regular use, making them poorly suited for chronic insomnia.
Risks for older adults: anticholinergic effects (confusion, urinary retention, dry mouth, constipation) are particularly problematic. The Beers Criteria — a list of medications to avoid in older adults — includes antihistamine sleep aids.
Special Considerations for Older Adults
Sleep changes naturally with age: more time in light sleep, more nighttime awakenings, earlier rising. Treating age-related changes as pathological insomnia requiring medication is often inappropriate.
Sleep medications carry elevated risks in older adults: - Fall and fracture risk (sedation, dizziness, confusion) - Next-day cognitive impairment - Driving impairment - Paradoxical agitation with some agents
The Beers Criteria recommends avoiding benzodiazepines, Z-drugs, and first-generation antihistamines in older adults as sleep aids. If medication is needed, low-dose doxepin (a tricyclic antidepressant with H1-blocking properties at 3–6 mg, far below antidepressant doses) is considered relatively safer.
Key Takeaways
- CBT-I is the first-line treatment for chronic insomnia — more effective and durable than medications.
- Z-drugs act on GABA-A receptors like benzodiazepines — effective short-term but carrying risks of complex sleep behaviors, tolerance, and dependence.
- All commonly prescribed sleep medications (Z-drugs, benzo hypnotics, DORAs) are DEA Schedule IV.
- Tolerance and rebound insomnia make benzodiazepines and Z-drugs unsuitable for long-term nightly use.
- Ramelteon (melatonin agonist) and DORAs (orexin antagonists) offer lower dependence profiles.
- OTC antihistamine sleep aids develop tolerance within days and are inappropriate for older adults.